LB Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Penn Plz Ste 1025, New York, New York,...Phone Number
(212) 605-0300Website
www.lbpharma.usRevenue
-Stock Symbol
LBRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About LB Pharmaceuticals
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. The company is based in New York, NY.Explore more
LB Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LB Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at LB Pharmaceuticals
Earning: See what the market has to say on LB Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once LB Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if LB Pharmaceuticals had a recent Job posting/layoffs
LB Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when LB Pharmaceuticals launches new products
Check if LB Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if LB Pharmaceuticals is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined LB Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to LB Pharmaceuticals
Compare insights from companies similar to LB Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
LB Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LB Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LB Pharmaceuticals.
LB Pharmaceuticals financials insights
Gather financial insights about LB Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$10M
2024
Series C
$75M
2025
IPO
$285M
LB Pharmaceuticals Tech Stack
A closer look at the technologies used by LB Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Product Development, Pharmaceuticals
Person-Based
Pharmaceuticals, Clinical Operations
LB Pharmaceuticals News & Media
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to scLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the “inducement grant” exception provided underLB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that […]LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LB Pharmaceuticals
Sign Up For FreeTo access detailed company insights
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. The company is based in New York, NY.... Read More
